Gilead Sciences, Inc.

    Jurisdiction
    United States
    LEI
    549300WTZWR07K8MNV44
    ISIN
    US3755581036 (GILD)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - General

    Scores

    InsiderPie Expert Score
    73 / 100
    Better than peer group:
    61 / 100
    Fair value (Benjamin Graham formula)
    €52.86 90.6% overvalued
    Financial strength (Piotroski F-Value)
    7 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. Read full profile

    Fundamentals

    Net revenue
    €24.62B
    Gross margin
    78.5%
    EBIT
    €6.87B
    EBIT margin
    27.9%
    Net income
    €5.38B
    Net margin
    21.9%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €25.56B +3.8% €9.13B +69.6%
    €26.95B +5.4% €9.91B +8.5%
    €28.64B +6.3% €10.77B +8.7%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    Last dividend amount
    $0.79
    Ex date
    Payment date
    Dividend payout ratio
    62.7%

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    O'Day Daniel Patrick Chairman & CEO -10K $113.63 -$1.14M
    Dickinson Andrew D Chief Financial Officer -2.5K $118.53 -$296.33K
    Mercier Johanna Chief Commercial Officer -28K $118.53 -$3.32M
    O'Day Daniel Patrick Chairman & CEO -10K $113.94 -$1.14M
    Dickinson Andrew D Chief Financial Officer -2.5K $111.03 -$277.58K

    Congress transactions

    Name Transaction date Value
    Val Hoyle October 10, 2025 $1.00K–$15.00K
    Val Hoyle September 12, 2025 $1.00K–$15.00K
    Jefferson Shreve June 22, 2025 $15.00K–$50.00K
    Marjorie Greene June 18, 2025 $1.00K–$15.00K
    Josh Gottheimer June 11, 2025 $1.00K–$15.00K

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 5.5M $610.80M +121K Buy
    Ray Dalio 503K $56.36M +42K Buy

    Earnings Calls

    Add to watchlist

    Notifications